> top > projects > sentences > docs > PubMed:12499404 > annotations
sentences Home  

PubMed:12499404 JSONTXT 54 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-124 Sentence denotes Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease.
T1 0-124 Sentence denotes Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease.
T1 0-124 Sentence denotes Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease.
TextSentencer_T2 125-345 Sentence denotes A mammalian-like sugar moiety was created in glycoprotein by Saccharomyces cerevisiae in combination with bacterial alpha-mannosidase to produce a more economic enzyme replacement therapy for patients with Fabry disease.
T2 125-345 Sentence denotes A mammalian-like sugar moiety was created in glycoprotein by Saccharomyces cerevisiae in combination with bacterial alpha-mannosidase to produce a more economic enzyme replacement therapy for patients with Fabry disease.
T2 125-345 Sentence denotes A mammalian-like sugar moiety was created in glycoprotein by Saccharomyces cerevisiae in combination with bacterial alpha-mannosidase to produce a more economic enzyme replacement therapy for patients with Fabry disease.
TextSentencer_T3 346-497 Sentence denotes We introduced the human alpha-galactosidase A (alpha-GalA) gene into an S. cerevisiae mutant that was deficient in the outer chains of N-linked mannan.
T3 346-497 Sentence denotes We introduced the human alpha-galactosidase A (alpha-GalA) gene into an S. cerevisiae mutant that was deficient in the outer chains of N-linked mannan.
T3 346-497 Sentence denotes We introduced the human alpha-galactosidase A (alpha-GalA) gene into an S. cerevisiae mutant that was deficient in the outer chains of N-linked mannan.
TextSentencer_T4 498-620 Sentence denotes The recombinant alpha-GalA contained both neutral (Man(8)GlcNAc(2)) and acidic ([Man-P](1-2)Man(8)GlcNAc(2)) sugar chains.
T4 498-620 Sentence denotes The recombinant alpha-GalA contained both neutral (Man(8)GlcNAc(2)) and acidic ([Man-P](1-2)Man(8)GlcNAc(2)) sugar chains.
T4 498-620 Sentence denotes The recombinant alpha-GalA contained both neutral (Man(8)GlcNAc(2)) and acidic ([Man-P](1-2)Man(8)GlcNAc(2)) sugar chains.
TextSentencer_T5 621-899 Sentence denotes Because an efficient incorporation of alpha-GalA into lysosomes of human cells requires mannose-6-phosphate (Man-6-P) residues that should be recognized by the specific receptor, we trimmed down the sugar chains of the alpha-GalA by a newly isolated bacterial alpha-mannosidase.
T5 621-899 Sentence denotes Because an efficient incorporation of alpha-GalA into lysosomes of human cells requires mannose-6-phosphate (Man-6-P) residues that should be recognized by the specific receptor, we trimmed down the sugar chains of the alpha-GalA by a newly isolated bacterial alpha-mannosidase.
T5 621-899 Sentence denotes Because an efficient incorporation of alpha-GalA into lysosomes of human cells requires mannose-6-phosphate (Man-6-P) residues that should be recognized by the specific receptor, we trimmed down the sugar chains of the alpha-GalA by a newly isolated bacterial alpha-mannosidase.
TextSentencer_T6 900-1113 Sentence denotes Treatment of the alpha-GalA with the alpha-mannosidase resulted in the exposure of a Man-6-P residue on a nonreduced end of oligosaccharide chains after the removal of phosphodiester-linked nonreduced-end mannose.
T6 900-1113 Sentence denotes Treatment of the alpha-GalA with the alpha-mannosidase resulted in the exposure of a Man-6-P residue on a nonreduced end of oligosaccharide chains after the removal of phosphodiester-linked nonreduced-end mannose.
T6 900-1113 Sentence denotes Treatment of the alpha-GalA with the alpha-mannosidase resulted in the exposure of a Man-6-P residue on a nonreduced end of oligosaccharide chains after the removal of phosphodiester-linked nonreduced-end mannose.
TextSentencer_T7 1114-1224 Sentence denotes The treated alpha-GalA was efficiently incorporated into fibroblasts derived from patients with Fabry disease.
T7 1114-1224 Sentence denotes The treated alpha-GalA was efficiently incorporated into fibroblasts derived from patients with Fabry disease.
T7 1114-1224 Sentence denotes The treated alpha-GalA was efficiently incorporated into fibroblasts derived from patients with Fabry disease.
TextSentencer_T8 1225-1356 Sentence denotes The uptake was three to four times higher than that of the nontreated alpha-GalA and was inhibited by the addition of 5 mM Man-6-P.
T8 1225-1356 Sentence denotes The uptake was three to four times higher than that of the nontreated alpha-GalA and was inhibited by the addition of 5 mM Man-6-P.
T8 1225-1497 Sentence denotes The uptake was three to four times higher than that of the nontreated alpha-GalA and was inhibited by the addition of 5 mM Man-6-P. Incorporated alpha-GalA was targeted to the lysosome, and hydrolyzed ceramide trihexoside accumulated in the Fabry fibroblasts after 5 days.
TextSentencer_T9 1357-1497 Sentence denotes Incorporated alpha-GalA was targeted to the lysosome, and hydrolyzed ceramide trihexoside accumulated in the Fabry fibroblasts after 5 days.
T9 1357-1497 Sentence denotes Incorporated alpha-GalA was targeted to the lysosome, and hydrolyzed ceramide trihexoside accumulated in the Fabry fibroblasts after 5 days.
TextSentencer_T10 1498-1607 Sentence denotes This method provides an effective and economic therapy for many lysosomal disorders, including Fabry disease.
T9 1498-1607 Sentence denotes This method provides an effective and economic therapy for many lysosomal disorders, including Fabry disease.
T10 1498-1607 Sentence denotes This method provides an effective and economic therapy for many lysosomal disorders, including Fabry disease.